Recombinant modified Bacillus anthracis protective antigen for use in vaccines

US8394387B1 · kind B1 · utility

Assignee

• The United States of America as Represented by the Secretary of the Department of Health and Human Services · US

Inventors

• Stephen H. Leppla · Bethesda, US
• Mary Jo Rosovitz · Germantown, US
• John B. Robbins · New York, US
• Rachel Schneerson · Bethesda, US
• S. Dana Hsu · Bethesda, US
• Joseph Shiloach · Rockville, US
• Delia M. Ramirez · Bethesda, US

Key dates

• Filing date: Jul 31, 2007
• Grant date: Mar 12, 2013
• Expiry date: Nov 7, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/53
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to improved methods of producing and recovering sporulation-deficient B. anthracis mutant stains, and for producing and recovering recombinant B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.